Regulating Tumor N⁶ -Methyladenosine Methylation Landscape using Hypoxia-Modulating OsS_x Nanoparticles

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Molecular Biology

Background:

• Epigenetic dysregulation and tumor hypoxia are key drivers of malignancy.
• N6-methyladenosine (m6A) RNA modification regulates gene expression and is implicated in cancer.
• Hypoxia-related genes play a critical role in tumor progression and chemoresistance.

Purpose of the Study:

• To develop a nanocatalyst for modulating tumor hypoxia and investigate its effect on RNA m6A methylation.
• To explore the relationship between catalytic nanomaterials and RNA modifications in cancer therapy.
• To assess the potential of OsSx-PEG nanoparticles in overcoming chemoresistance.

Main Methods:

• Synthesis and characterization of OsSx-PEG nanoparticles (NPs) as an O2 modulator.
• In vitro assessment of NP effects on hypoxia-related gene expression and m6A methylation levels.
• In vivo studies using DOX@OsSx-PEG NPs to evaluate therapeutic efficacy in a tumor model.

Main Results:

• OsSx-PEG NPs effectively downregulated hypoxia-related genes and modulated tumor hypoxia.
• NPs elevated RNA m6A methylation, leading to m6A-dependent mRNA degradation of hypoxia-related genes.
• OsSx-PEG NPs regulated the expression of key RNA m6A methyltransferases and demethylases.
• In vivo studies demonstrated that DOX@OsSx-PEG NPs modulated tumor hypoxia and m6A methylation.

Conclusions:

• Catalytic nanomaterials can modulate tumor hypoxia and influence RNA m6A methylation.
• Regulating RNA m6A methylation presents a novel strategy to target hypoxia-related genes and overcome chemoresistance.
• This research opens new avenues for understanding nanomaterial mechanisms and developing targeted cancer therapies.